The Experts below are selected from a list of 27 Experts worldwide ranked by ideXlab platform
Stephanos J Hadziyannis - One of the best experts on this subject based on the ideXlab platform.
-
Peginterferon Alpha2a and ribavirin combination therapy in chronic hepatitis c a randomized study of treatment duration and ribavirin dose
Annals of Internal Medicine, 2004Co-Authors: Stephanos J Hadziyannis, Hoel Sette, Timothy R Morgan, Vijayan Balan, M Diago, Patrick Marcellin, Giuliano Ramadori, Henry C Bodenheimer, David Bernstein, M RizzettoAbstract:BACKGROUND: Treatment with pegylated interferon (Peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C. OBJECTIVE: To assess the efficacy and safety of 24 or 48 weeks of treatment with Peginterferon-Alpha2a plus a low or standard dose of ribavirin. DESIGN: Randomized, double-blind trial. SETTING: 99 international centers. PATIENTS: 1311 patients with chronic hepatitis C. PATIENTS: 1311 patients with chronic hepatitis C. INTERVENTION: Peginterferon-?2a, 180 ?/wk, for 24 or 48 weeks plus a low-dose (800 mg/d) or standard weight-based dose (1000 or 1200 mg/d) of ribavirin. Measurement: Sustained virologic response: undetectable HCV RNA concentration at the end of treatment and during 12 to 24 weeks of follow-up. RESULTS: Overall and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribavirin was statistically superior to low-dose ribavirin. In patients with HCV genotype 1, absolute differences in sustained virologic response rates between 48 and 24 weeks of treatment were 11.2% (95% CI, 3.6% to 18.9%) and 11.9% (CI, 4.7% to 18.9%), respectively, between standard- and low-dose ribavirin. Sustained virologic response rates for Peginterferon-Alpha2a and standard-dose ribavirin for 48 weeks were 63% (CI, 59% to 68%) overall and 52% (CI, 46% to 58%) in patients with HCV genotype 1. In patients with HCV genotypes 2 or 3, the sustained virologic response rates in the 4 treatment groups were not statistically significantly different. CONCLUSION: Treatment with Peginterferon-?2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.
-
Peginterferon Alpha2a 40 kda for chronic hepatitis c
Expert Opinion on Pharmacotherapy, 2003Co-Authors: Stephanos J Hadziyannis, George V PapatheodoridisAbstract:Pegylated IFN-α2a (PEG-IFN-α2a [40 kDa]; Pegasys®, Hoffmann-La Roche) is a new subcutaneous formulation of IFN-α2a, produced by its attachment to a 40 kDa branched polyethylene glycol moiety by a stable amide bond. PEG-IFN-α2a 180 μg once-weekly has enhanced pharmacokinetic and pharmacodynamic properties which translate into significantly improved efficacy and similar safety and tolerability compared with IFN-α in patients with chronic hepatitis C even with underlying cirrhosis. The combination of PEG-IFN-α2a (40 kDa) plus ribavirin produces significantly better sustained virological responses than the combination of IFN-α2b and ribavirin, while it is accompanied by a similar or even lower incidence of adverse events and better quality of life. PEG-IFN-α2a (40 kDa) is the first pegylated IFN-α for which evidence-based recommendations can be made on optimum therapy duration and ribavirin dose according to HCV genotype. PEG-IFN-α2a (40 kDa) is expected to improve the efficacy and tolerability of treatment f...
M Rizzetto - One of the best experts on this subject based on the ideXlab platform.
-
Peginterferon Alpha2a and ribavirin combination therapy in chronic hepatitis c a randomized study of treatment duration and ribavirin dose
Annals of Internal Medicine, 2004Co-Authors: Stephanos J Hadziyannis, Hoel Sette, Timothy R Morgan, Vijayan Balan, M Diago, Patrick Marcellin, Giuliano Ramadori, Henry C Bodenheimer, David Bernstein, M RizzettoAbstract:BACKGROUND: Treatment with pegylated interferon (Peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C. OBJECTIVE: To assess the efficacy and safety of 24 or 48 weeks of treatment with Peginterferon-Alpha2a plus a low or standard dose of ribavirin. DESIGN: Randomized, double-blind trial. SETTING: 99 international centers. PATIENTS: 1311 patients with chronic hepatitis C. PATIENTS: 1311 patients with chronic hepatitis C. INTERVENTION: Peginterferon-?2a, 180 ?/wk, for 24 or 48 weeks plus a low-dose (800 mg/d) or standard weight-based dose (1000 or 1200 mg/d) of ribavirin. Measurement: Sustained virologic response: undetectable HCV RNA concentration at the end of treatment and during 12 to 24 weeks of follow-up. RESULTS: Overall and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribavirin was statistically superior to low-dose ribavirin. In patients with HCV genotype 1, absolute differences in sustained virologic response rates between 48 and 24 weeks of treatment were 11.2% (95% CI, 3.6% to 18.9%) and 11.9% (CI, 4.7% to 18.9%), respectively, between standard- and low-dose ribavirin. Sustained virologic response rates for Peginterferon-Alpha2a and standard-dose ribavirin for 48 weeks were 63% (CI, 59% to 68%) overall and 52% (CI, 46% to 58%) in patients with HCV genotype 1. In patients with HCV genotypes 2 or 3, the sustained virologic response rates in the 4 treatment groups were not statistically significantly different. CONCLUSION: Treatment with Peginterferon-?2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.
Adrian M Di Bisceglie - One of the best experts on this subject based on the ideXlab platform.
-
high resolution quantification of hepatitis c virus genome wide mutation load and its correlation with the outcome of Peginterferon Alpha2a and ribavirin combination therapy
PLOS ONE, 2014Co-Authors: Weihua Wang, Xiaoan Zhang, Yanjuan Xu, George M Weinstock, Adrian M Di BisceglieAbstract:Hepatitis C virus (HCV) is a highly mutable RNA virus and circulates as a heterogeneous population in individual patients. The magnitude of such population heterogeneity has long been proposed to be linked with diverse clinical phenotypes, including antiviral therapy. Yet data accumulated thus far are fairly inconclusive. By the integration of long RT-PCR with 454 sequencing, we have built a pipeline optimized for the quantification of HCV genome-wide mutation load at 1% resolution of mutation frequency, followed by a retrospective study to examine the role of HCV mutation load in Peginterferon-Alpha2a and ribavirin combination antiviral therapy. Genome-wide HCV mutation load varied widely with a range from 92 to 1639 mutations and presented a Poisson distribution among 56 patients (Kolmogorov-Smirnov statistic = 0.078, p = 0.25). Patients achieving sustained virological response (n = 26) had significantly lower mutation loads than that in null responders (n = 30) (mean and standard derivation: 524±279 vs. 805±271, p = 0.00035). All 36,818 mutations detected in 56 patients displayed a power-law distribution in terms of mutation frequency in viral population. The low-frequency mutation load, but not the high-frequency load, was proportional firmly to the total mutation load. In-depth analyses revealed that intra-patient HCV population structure was shaped by multiple factors, including immune pressure, strain difference and genetic drift. These findings explain previous conflicting reports using low-resolution methods and highlight a dominant role of natural selection in response to therapeutic intervention. By attaining its signatures from complex interaction between host and virus, the high-resolution quantification of HCV mutation load predicts outcomes from interferon-based antiviral therapy and could also be a potential biomarker in other clinical settings.
Timothy R Morgan - One of the best experts on this subject based on the ideXlab platform.
-
Peginterferon Alpha2a and ribavirin combination therapy in chronic hepatitis c a randomized study of treatment duration and ribavirin dose
Annals of Internal Medicine, 2004Co-Authors: Stephanos J Hadziyannis, Hoel Sette, Timothy R Morgan, Vijayan Balan, M Diago, Patrick Marcellin, Giuliano Ramadori, Henry C Bodenheimer, David Bernstein, M RizzettoAbstract:BACKGROUND: Treatment with pegylated interferon (Peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C. OBJECTIVE: To assess the efficacy and safety of 24 or 48 weeks of treatment with Peginterferon-Alpha2a plus a low or standard dose of ribavirin. DESIGN: Randomized, double-blind trial. SETTING: 99 international centers. PATIENTS: 1311 patients with chronic hepatitis C. PATIENTS: 1311 patients with chronic hepatitis C. INTERVENTION: Peginterferon-?2a, 180 ?/wk, for 24 or 48 weeks plus a low-dose (800 mg/d) or standard weight-based dose (1000 or 1200 mg/d) of ribavirin. Measurement: Sustained virologic response: undetectable HCV RNA concentration at the end of treatment and during 12 to 24 weeks of follow-up. RESULTS: Overall and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribavirin was statistically superior to low-dose ribavirin. In patients with HCV genotype 1, absolute differences in sustained virologic response rates between 48 and 24 weeks of treatment were 11.2% (95% CI, 3.6% to 18.9%) and 11.9% (CI, 4.7% to 18.9%), respectively, between standard- and low-dose ribavirin. Sustained virologic response rates for Peginterferon-Alpha2a and standard-dose ribavirin for 48 weeks were 63% (CI, 59% to 68%) overall and 52% (CI, 46% to 58%) in patients with HCV genotype 1. In patients with HCV genotypes 2 or 3, the sustained virologic response rates in the 4 treatment groups were not statistically significantly different. CONCLUSION: Treatment with Peginterferon-?2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.
Vijayan Balan - One of the best experts on this subject based on the ideXlab platform.
-
Peginterferon Alpha2a and ribavirin combination therapy in chronic hepatitis c a randomized study of treatment duration and ribavirin dose
Annals of Internal Medicine, 2004Co-Authors: Stephanos J Hadziyannis, Hoel Sette, Timothy R Morgan, Vijayan Balan, M Diago, Patrick Marcellin, Giuliano Ramadori, Henry C Bodenheimer, David Bernstein, M RizzettoAbstract:BACKGROUND: Treatment with pegylated interferon (Peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C. OBJECTIVE: To assess the efficacy and safety of 24 or 48 weeks of treatment with Peginterferon-Alpha2a plus a low or standard dose of ribavirin. DESIGN: Randomized, double-blind trial. SETTING: 99 international centers. PATIENTS: 1311 patients with chronic hepatitis C. PATIENTS: 1311 patients with chronic hepatitis C. INTERVENTION: Peginterferon-?2a, 180 ?/wk, for 24 or 48 weeks plus a low-dose (800 mg/d) or standard weight-based dose (1000 or 1200 mg/d) of ribavirin. Measurement: Sustained virologic response: undetectable HCV RNA concentration at the end of treatment and during 12 to 24 weeks of follow-up. RESULTS: Overall and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribavirin was statistically superior to low-dose ribavirin. In patients with HCV genotype 1, absolute differences in sustained virologic response rates between 48 and 24 weeks of treatment were 11.2% (95% CI, 3.6% to 18.9%) and 11.9% (CI, 4.7% to 18.9%), respectively, between standard- and low-dose ribavirin. Sustained virologic response rates for Peginterferon-Alpha2a and standard-dose ribavirin for 48 weeks were 63% (CI, 59% to 68%) overall and 52% (CI, 46% to 58%) in patients with HCV genotype 1. In patients with HCV genotypes 2 or 3, the sustained virologic response rates in the 4 treatment groups were not statistically significantly different. CONCLUSION: Treatment with Peginterferon-?2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.